Peptides in Metabolic Research: Australian Overview
For laboratory research use only. Not for human use. Research use only.
A growing body of preclinical and clinical research has examined the role of peptides in metabolic regulation, energy homeostasis, and body weight management. In Australia, researchers studying obesity, metabolic syndrome, and related conditions have increasing access to research-grade peptides that target key metabolic pathways. This overview covers the most studied peptides in metabolic and weight research.
GLP-1 and GIP Receptor Agonists
The most extensively studied peptides in metabolic research are GLP-1 (glucagon-like peptide-1) receptor agonists. GLP-1 is an incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Semaglutide, a GLP-1 receptor agonist, demonstrated approximately 15% mean body weight reduction in the STEP clinical trial programme.
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated approximately 22% mean body weight reduction in the SURMOUNT-1 trial. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, demonstrated approximately 24% mean body weight reduction in Phase 2 trials — the largest pharmacological weight reduction observed to date.
Tesamorelin and Growth Hormone Research
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It has been studied in the context of visceral adiposity — specifically HIV-associated lipodystrophy — and received FDA approval for this indication. Preclinical research has also examined its apparent effects on body composition and metabolic parameters.
Growth hormone secretagogues including CJC-1295 and Ipamorelin have been studied in preclinical models for their apparent effects on body composition, muscle mass, and fat distribution. These peptides stimulate growth hormone release from the pituitary gland through different mechanisms.
MOTS-c and Mitochondrial Metabolism
MOTS-c, a mitochondria-derived peptide, has been studied in preclinical models for its apparent effects on insulin sensitivity and metabolic regulation. Rodent studies have observed apparent prevention of diet-induced obesity and improved glucose homeostasis following MOTS-c administration.
The mitochondrial origin of MOTS-c and its apparent role in coordinating cellular metabolic responses makes it a unique research tool for studying the relationship between mitochondrial function and systemic metabolism.
Research Supply in Australia
PeptideIQ supplies research-grade Retatrutide, Tirzepatide, Semaglutide, Tesamorelin, MOTS-c, and other metabolic research peptides in Australia. All products are third-party HPLC tested with full Certificates of Analysis. For laboratory research use only.
Frequently Asked Questions
What is the most studied peptide for weight loss research?
Retatrutide has demonstrated the largest weight reduction in clinical trials to date (24.2% in Phase 2). GLP-1 agonists including Semaglutide and dual agonists including Tirzepatide are also extensively studied. All are available from PeptideIQ for research use only.
Are weight loss peptides legal in Australia?
Research-grade peptides for metabolic research are available in Australia for laboratory research use only. They are not approved for human therapeutic use unless specifically listed on the ARTG.
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.